Finance

Beta
Lists
Equity sectors
Symbols
Symbols
Price
Change
% Change
Trend
Prev Close
Açın
High
Low
Volume
Mkt Cap
SIXB
Materials
SIXB
Materials
SIXB
-1,22%
1.078,16
-13,35
-1,22%
—1.091,511.090,401.090,401.075,55——
SIXC
Communications
SIXC
Communications
SIXC
-0,28%
608,40
-1,71
-0,28%
—610,11610,11610,29606,17——
SIXE
Energy
SIXE
Energy
SIXE
+0,64%
1.245,96
+7,98
+0,64%
—1.237,981.237,831.252,411.225,03——
SIXI
Industrials
SIXI
Industrials
SIXI
-0,95%
1.728,14
-16,57
-0,95%
—1.744,711.740,951.747,291.721,57——
SIXM
Financials
SIXM
Financials
SIXM
-0,46%
637,24
-2,94
-0,46%
—640,18639,92643,19636,28——
SIXR
Staples
SIXR
Staples
SIXR
-0,66%
843,98
-5,60
-0,66%
—849,58845,27851,68841,28——
SIXRE
Real estate
SIXRE
Real estate
SIXRE
-0,46%
216,49
-0,99
-0,46%
—217,48217,48218,16216,37——
SIXT
Technology
SIXT
Technology
SIXT
-0,15%
3.255,93
-4,76
-0,15%
—3.260,693.273,363.287,813.240,78——
SIXU
Utilities
SIXU
Utilities
SIXU
-0,40%
938,68
-3,77
-0,40%
—942,45939,39948,80934,04——
SIXV
Health care
SIXV
Health care
SIXV
-0,43%
1.460,58
-6,28
-0,43%
—1.466,801.464,701.467,191.458,68——
SIXY
Discretionary
SIXY
Discretionary
SIXY
-0,99%
2.373,79
-23,71
-0,99%
—2.397,502.395,032.412,012.370,64——
GIS:FRA
Gilead Sciences Inc
113,46 €
+3,47%
(+3,80) 1D
4 may, 18:05:27 GMT+2  ·   EUR
All symbols
SymbolPriceChange% Change
Generating top insights for GIS...
Açın
112,02 €
High
113,46 €
Low
112,02 €
Mkt. cap
164,28 mlrd
Avg. vol.
330,00
Volume
252,00
52-wk high
132,00 €
52-wk low
82,61 €
No. of employees
17K
News stories
From sources across the web
Profile
Gilead Sciences, Inc. is an American biopharmaceutical company headquartered in Foster City, California, that focuses on researching and developing antiviral drugs used in the treatment of HIV/AIDS, hepatitis B, hepatitis C, influenza, and COVID-19, including ledipasvir/sofosbuvir and sofosbuvir. It has recently expanded into different therapeutic areas such as oncology and inflammation. Gilead is a member of the Nasdaq-100 and the S&P 100. Gilead was founded in 1987 under the name Oligogen by Michael L. Riordan. The original name was a reference to oligonucleotides, small strands of DNA used to target genetic sequences. Gilead held its initial public offering in 1992, and successfully developed drugs like Tamiflu and Vistide that decade. In the 2000s, Gilead received approval for drugs including Viread and Hepsera, among others. It began evolving from a biotechnology company into a pharmaceutical company, acquiring several subsidiaries, though it still relied heavily on contracting to manufacture its drugs. The company continued its growth in the 2010s. Wikipedia
About Gilead Sciences Inc
CEODaniel O'Day
Employees17K
Founded22 iyn 1987
HeadquartersFoster City, Kaliforniya, Amerika Birləşmiş Ştatları
Sector-
Websitegilead.com
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
mar 2025
iyn 2025
sen 2025
dek 2025
Revenue
6,67 mlrd
7,08 mlrd
7,77 mlrd
7,92 mlrd
Cost of goods sold
1,54 mlrd
1,50 mlrd
1,57 mlrd
1,62 mlrd
Cost of revenue
1,54 mlrd
1,50 mlrd
1,57 mlrd
1,62 mlrd
Research and development expenses
1,34 mlrd
1,45 mlrd
1,33 mlrd
1,57 mlrd
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
1,22 mlrd
1,36 mlrd
1,35 mlrd
1,78 mlrd
Operating expense
2,56 mlrd
2,81 mlrd
2,69 mlrd
3,34 mlrd
Total operating expenses
4,10 mlrd
4,31 mlrd
4,26 mlrd
4,96 mlrd
Operating income
2,57 mlrd
2,77 mlrd
3,51 mlrd
2,96 mlrd
Other non operating income
11,00 mln
13,00 mln
-23,00 mln
51,00 mln
EBT including unusual items
1,65 mlrd
2,43 mlrd
3,64 mlrd
2,08 mlrd
EBT excluding unusual items
2,40 mlrd
2,58 mlrd
3,34 mlrd
2,80 mlrd
Income tax expense
334,00 mln
468,00 mln
589,00 mln
-105,00 mln
Effective tax rate
20,25%
19,28%
16,18%
-5,05%
Other operating expenses
-
-
-
-
Net income
1,32 mlrd
1,96 mlrd
3,05 mlrd
2,18 mlrd
Net profit margin
19,72%
27,68%
39,28%
27,55%
Earnings per share
1,81
2,01
2,47
1,86
Interest and investment income
94,00 mln
73,00 mln
88,00 mln
95,00 mln
Interest expense
-260,00 mln
-254,00 mln
-256,00 mln
-255,00 mln
Net interest expenses
-166,00 mln
-181,00 mln
-168,00 mln
-160,00 mln
Depreciation and amortization charges
-
-
-
-
EBITDA
3,26 mlrd
3,46 mlrd
4,20 mlrd
3,65 mlrd
Gain or loss from assets sale
-
-
-
-
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

My tasks
You haven't created a task yet
Your tasks will appear here. Schedule tasks and put Google Finance to work while you're away.
Templates
Watchlist briefing
A daily pre-market analysis of your watchlist
Upcoming Earnings
Upcoming earnings reports in the week
Abnormal Volatility & Volume
Volatility and volume early warning today
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer